Literature DB >> 8519448

High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV.

B Cribier1, D Rey, C Schmitt, J M Lang, A Kirn, F Stoll-Keller.   

Abstract

OBJECTIVE: To compare hepatitis C virus (HCV) load in patients infected with HCV alone and those coinfected with HIV, and to evaluate the antibody response to HCV in the case of HIV infection.
DESIGN: Patients coinfected with both HCV and HIV have been shown to develop hepatic changes more rapidly, which may be due to an interaction between HCV and HIV. In a prospective study, serum samples were taken from 150 patients.
METHODS: Using reverse transcription followed by polymerase chain reaction and the branched DNA assay, we detected HCV RNA in 75 patients coinfected with HIV and HCV and in 75 patients infected with HCV alone. The HIV RNA was also quantified by the branched DNA assay and the p24 antigenaemia was determined by enzyme-linked immunosorbent assay. The immune response to HCV was studied in the 150 patients by the use of third generation recombinant immunoblot assay (RIBA).
RESULTS: Although a comparable number of patients had detectable HCV viraemia in both groups, HCV RNA was quantifiable in 79% of HIV-positive patients and in only 43% of HIV-negative patients (P < 10(-5)), and the mean HCV RNA level was much higher in the HIV-positive group than in the HIV-negative group (P < 10(-7)). The quantity of HCV RNA did not correlate with the CD4 count, p24 antigenaemia or HIV RNA level. The analysis of RIBA showed 14.7% indeterminate or negative results in the HIV-positive group and only 4% indeterminate results in the HIV-negative group. HIV-positive patients had reactivity to less antigen bands than HIV-negative patients (P < 10(-3)), and they had a weaker reactivity to c100, c33c and NS5 antigen bands than HIV-negative patients.
CONCLUSION: Our results show that in the case of HIV infection, the HCV RNA levels are strongly increased, but HCV load is not linked to the immunosuppression induced by HIV; therefore, the present data do not support the hypothesis of a direct interaction between HIV and HCV.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8519448     DOI: 10.1097/00002030-199510000-00003

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  32 in total

1.  Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV.

Authors:  C L Cherry; J S Affandi; B J Brew; J Creighton; S Djauzi; D J Hooker; D Imran; A Kamarulzaman; P Kamerman; J C McArthur; R D Moore; P Price; K Smyth; I L Tan; S Vanar; A Wadley; S L Wesselingh; E Yunihastuti
Journal:  Neurology       Date:  2010-05-11       Impact factor: 9.910

Review 2.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

3.  Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China.

Authors:  Han-Zhu Qian; Sten H Vermund; Richard A Kaslow; Christopher S Coffey; Eric Chamot; Zhongmin Yang; Xiaochun Qiao; Yuliang Zhang; Xiaoming Shi; Yan Jiang; Yiming Shao; Ning Wang
Journal:  AIDS       Date:  2006-06-26       Impact factor: 4.177

4.  Altered expression of the tetraspanin CD81 on B and T lymphocytes during HIV-1 infection.

Authors:  L Meroni; L Milazzo; B Menzaghi; R Mazzucchelli; D Mologni; P Morelli; V Broggini; F Adorni; M Galli; A Riva
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

5.  Human T-cell lymphotropic virus infection in pregnant women in Spain.

Authors:  C Tuset; M Gutiérrez; C Carbonell; T Tuset; V Soriano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-10       Impact factor: 3.267

6.  Interferon-alpha therapy for chronic hepatitis C in special patient populations.

Authors:  P Marcellin; N Boyer; J P Behamou; S Erlinger
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

7.  Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users.

Authors:  Basmattee Boodram; Ronald C Hershow; Scott J Cotler; Lawrence J Ouellet
Journal:  Drug Alcohol Depend       Date:  2011-07-02       Impact factor: 4.492

8.  Hepatitis C and HIV-1 coinfection.

Authors:  A H Mohsen; P Easterbrook; C B Taylor; S Norris
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

9.  Assessment of a hepatitis C virus antibody assay in saliva for epidemiological studies.

Authors:  P Y Bello; C Pasquier; P Gourney; J Puel; J Izopet
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

10.  Dissociation of serum and liver hepatitis C virus RNA levels in patients coinfected with human immunodeficiency virus and treated with antiretroviral drugs.

Authors:  Milena Furione; Renato Maserati; Marta Gatti; Fausto Baldanti; Agostino Cividini; Raffaele Bruno; Giuseppe Gerna; Mario U Mondelli
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.